{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:53:04Z","timestamp":1787507584416,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00108-025-01935-z","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:28:46Z","timestamp":1753435726000},"page":"1209-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-Pl\u00e4ttchenfaktor-4(PF4)-assoziierte Erkrankungen \u2013 von der Arzneimittelnebenwirkung zur Thromboseneigung","Antiplatelet factor\u00a04 (PF4)-associated disorders: from drug adverse reactions to thrombotic disease"],"prefix":"10.1007","volume":"66","author":[{"given":"Linda","family":"Sch\u00f6nborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"1935_CR1","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMcp1411910","volume":"373","author":"A Greinacher","year":"2015","unstructured":"Greinacher\u00a0A (2015) Heparin-Induced Thrombocytopenia. N\u00a0Engl J Med 373:1883\u20131884","journal-title":"N Engl J Med"},{"key":"1935_CR2","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher\u00a0A, Thiele\u00a0T, Warkentin\u00a0TE et\u00a0al (2021) Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N\u00a0Engl J Med 384:2092\u20132101","journal-title":"N Engl J Med"},{"key":"1935_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJMc2307721","volume":"389","author":"TE Warkentin","year":"2023","unstructured":"Warkentin\u00a0TE, Baskin-Miller\u00a0J, Raybould\u00a0AL et\u00a0al (2023) Adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies. N\u00a0Engl J Med 389:574\u2013577","journal-title":"N Engl J Med"},{"key":"1935_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1056\/NEJMc2309016","volume":"389","author":"E Lindhoff-Last","year":"2023","unstructured":"Lindhoff-Last\u00a0E, Sch\u00f6nborn\u00a0L, Zaninetti\u00a0C et\u00a0al (2023) Rescue therapy in chronic prothrombotic autoimmune anti-PF4 disorder. N\u00a0Engl J Med 389:1339\u20131341","journal-title":"N Engl J Med"},{"key":"1935_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMoa2415930","volume":"392","author":"JJ Wang","year":"2025","unstructured":"Wang\u00a0JJ, Warkentin\u00a0TE, Schonborn\u00a0L et\u00a0al (2025) VITT-like Monoclonal Gammopathy of Thrombotic Significance. N\u00a0Engl J Med 392:995\u20131005","journal-title":"N Engl J Med"},{"key":"1935_CR6","doi-asserted-by":"publisher","first-page":"102729","DOI":"10.1016\/j.rpth.2025.102729","volume":"9","author":"L M\u00fcller","year":"2025","unstructured":"M\u00fcller\u00a0L, Wang\u00a0JJ, Dabbiru\u00a0VAS et\u00a0al (2025) Anti-Platelet factor\u00a04 immunothrombosis\u2014not just heparin and vaccine triggers. Res Pract Thromb Haemostasis 9:102729","journal-title":"Res Pract Thromb Haemostasis"},{"issue":"1134\u20131125","key":"1935_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00108-010-2594-5","volume":"51","author":"T Thiele","year":"2010","unstructured":"Thiele\u00a0T, Althaus\u00a0K, Greinacher\u00a0A (2010) Heparin-induced thrombocytopenia. Internist 51(1134\u20131125):1127\u20131132","journal-title":"Internist"},{"key":"1935_CR8","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","volume":"385","author":"S Pavord","year":"2021","unstructured":"Pavord\u00a0S, Scully\u00a0M, Hunt\u00a0BJ et\u00a0al (2021) Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N\u00a0Engl J Med 385:1680\u20131689","journal-title":"N Engl J Med"},{"key":"1935_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","volume":"4","author":"GK Lo","year":"2006","unstructured":"Lo\u00a0GK, Juhl\u00a0D, Warkentin\u00a0TE et\u00a0al (2006) Evaluation of pretest clinical score (4 T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J\u00a0Thromb Haemost 4:759\u2013765","journal-title":"J Thromb Haemost"},{"key":"1935_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.seminhematol.2022.02.005","volume":"59","author":"TE Warkentin","year":"2022","unstructured":"Warkentin\u00a0TE (2022) Platelet-activating anti-PF4 disorders: An overview. Semin Hematol 59:59\u201371","journal-title":"Semin Hematol"},{"key":"1935_CR11","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jth.13813","volume":"15","author":"A Greinacher","year":"2017","unstructured":"Greinacher\u00a0A, Selleng\u00a0K, Warkentin\u00a0TE (2017) Autoimmune heparin-induced thrombocytopenia. J\u00a0Thromb Haemost 15:2099\u20132114","journal-title":"J Thromb Haemost"},{"key":"1935_CR12","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.vaccine.2024.01.045","volume":"42","author":"L Sch\u00f6nborn","year":"2024","unstructured":"Sch\u00f6nborn\u00a0L, Pavord\u00a0S, Chen\u00a0VMY et\u00a0al (2024) Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 42:1799\u20131811","journal-title":"Vaccine"},{"key":"1935_CR13","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMc2112974","volume":"385","author":"F Salih","year":"2021","unstructured":"Salih\u00a0F, Sch\u00f6nborn\u00a0L, Kohler\u00a0S et\u00a0al (2021) Vaccine-Induced Thrombocytopenia with Severe Headache. N\u00a0Engl J Med 385:2103\u20132105","journal-title":"N Engl J Med"},{"key":"1935_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMc2413301","volume":"392","author":"S H\u00e4usler","year":"2025","unstructured":"H\u00e4usler\u00a0S, Sch\u00f6nborn\u00a0L, Gradl\u00a0J et\u00a0al (2025) Maternal Anti-PF4 Antibodies as Cause of Neonatal Stroke. N\u00a0Engl J Med 392:719\u2013721","journal-title":"N Engl J Med"},{"key":"1935_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jth.15362","volume":"19","author":"S Platton","year":"2021","unstructured":"Platton\u00a0S, Bartlett\u00a0A, MacCallum\u00a0P et\u00a0al (2021) Evaluation of laboratory assays for anti-platelet factor\u00a04 antibodies after ChAdOx1 nCOV-19 vaccination. J\u00a0Thromb Haemost 19:2007\u20132013","journal-title":"J Thromb Haemost"},{"key":"1935_CR16","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3324\/haematol.2021.279000","volume":"106","author":"K Althaus","year":"2021","unstructured":"Althaus\u00a0K, Moller\u00a0P, Uzun\u00a0G et\u00a0al (2021) Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 106:2170\u20132179","journal-title":"Haematologica"},{"key":"1935_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa2107051","volume":"385","author":"A Bourguignon","year":"2021","unstructured":"Bourguignon\u00a0A, Arnold\u00a0DM, Warkentin\u00a0TE et\u00a0al (2021) Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. N\u00a0Engl J Med 385:720\u2013728","journal-title":"N Engl J Med"},{"key":"1935_CR18","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2024-207999","volume":"144","author":"A Padmanabhan","year":"2024","unstructured":"Padmanabhan\u00a0A, Splinter\u00a0N, Mauch\u00a0E et\u00a0al (2024) Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis. Blood 144:3996","journal-title":"Blood"},{"key":"1935_CR19","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker\u00a0A, Arepally\u00a0GM, Chong\u00a0BH et\u00a0al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:3360\u20133392","journal-title":"Blood Adv"},{"key":"1935_CR20","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1111\/jth.15862","volume":"20","author":"L Sch\u00f6nborn","year":"2023","unstructured":"Sch\u00f6nborn\u00a0L, Seck\u00a0SE, Thiele\u00a0T et\u00a0al (2023) Long-term outcome in Vaccine-induced Immune Thrombocytopenia and Thrombosis. J\u00a0Thromb Haemost 20:2579\u20132586","journal-title":"J Thromb Haemost"},{"key":"1935_CR21","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.athoracsur.2003.09.034","volume":"76","author":"TE Warkentin","year":"2003","unstructured":"Warkentin\u00a0TE, Greinacher\u00a0A (2003) Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76:2121\u20132131","journal-title":"Ann Thorac Surg"},{"key":"1935_CR22","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJMc2112760","volume":"385","author":"L Sch\u00f6nborn","year":"2021","unstructured":"Sch\u00f6nborn\u00a0L, Thiele\u00a0T, Kaderali\u00a0L et\u00a0al (2021) Decline in Pathogenic Antibodies over Time in VITT. N\u00a0Engl J Med 385:1815\u20131816","journal-title":"N Engl J Med"},{"key":"1935_CR23","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","volume":"130","author":"TE Warkentin","year":"2017","unstructured":"Warkentin\u00a0TE, Pai\u00a0M, Linkins\u00a0LA (2017) Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood 130:1104\u20131113","journal-title":"Blood"},{"key":"1935_CR24","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel\u00a0J, Verhamme\u00a0P, Potpara\u00a0TS et\u00a0al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin\u00a0K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart\u00a0J 39:1330\u20131393","journal-title":"Eur Heart J"},{"key":"1935_CR25","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1182\/bloodadvances.2024014167","volume":"9","author":"J Zlamal","year":"2025","unstructured":"Zlamal\u00a0J, Ripoll\u00a0VM, Lee\u00a0CSM et\u00a0al (2025) Platelet spleen tyrosine kinase is a\u00a0key regulator of anti-PF4 antibody-induced immunothrombosis. Blood Adv 9:1772\u20131785","journal-title":"Blood Adv"},{"key":"1935_CR26","unstructured":"Sch\u00f6nborn L (2025) BioRender. https:\/\/BioRender.com\/jkg1rkw"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01935-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01935-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01935-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T19:35:52Z","timestamp":1761680152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01935-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1935"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01935-z","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"6 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Greinacher erhielt pers\u00f6nliche Honorare und Forschungsunterst\u00fctzung von Instrumentation Laboratory, Macopharma, Portola, Biokit, Sanofi-Aventis, Blau Farmaceutica, Prosensa\/BioMarin, DRK-BSD NSTOB, DRK-BSD Baden-W\u00fcrtemberg\/Hessen, Roche, GTH e.\u202fV., Deutsche Forschungsgemeinschaft, Robert Koch-Institut, Veralox, Dilaflor, Vakzine Projekt Management GmbH, GIZ Else-Kr\u00f6ner-Fresenius-Stiftung, AstraZeneca, Janssen Vaccines & Prevention B.V., Takeda Pharma, Falk Foundation e.\u202fV., Europ\u00e4ische Arzneimittel-Agentur, Mylan Deutschland, Biotest, die alle au\u00dferhalb der eingereichten Arbeit liegen. T.\u00a0Thiele erhielt pers\u00f6nliche Honorare und Reisekostenunterst\u00fctzung von Bristol Myers Squibb, Pfizer, Bayer, Chugai Pharma, Novo Nordisk, Novartis, Daiichi Sankyo und LFB Pharma, Leo Pharma, die alle au\u00dferhalb der eingereichten Arbeit liegen. L.\u00a0Sch\u00f6nborn gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}